Literature DB >> 11313670

Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.

A Salar1, J Sierra, M Gandarillas, M D Caballero, J Marín, J J Lahuerta, J García-Conde, R Arranz, A León, J Zuazu, J García-Laraña, A López-Guillermo, M A Sanz, A Grañena, J C García, E Conde.   

Abstract

We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO. Among them, 139 (35%) were autografted in 1st CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive disease and 46 (12%) had chemoresistant disease. Conditioning consisted of chemotherapy-only in 348 patients (BEAM, 164; BEAC, 145; and CBV, 39) and radiochemotherapy with CY and TBI in 47. Median times to granulocyte, platelet recovery and to discharge were significantly shorter in the chemotherapy-only group. Early transplant-related mortality was significantly higher when using CY-TBI. After a median follow-up of 28 months, overall survival (OS) at 8 years of patients conditioned with BEAM or BEAC (58% (95% CI 50-66%)) was more favorable than with CBV (40% (95% CI 24-56%)), and significantly better than with CY-TBI (31% (95% CI 18-44%)). Multivariate analysis revealed that patients conditioned with chemotherapy-only regimens had improved OS, disease-free (DFS) and relapse-free survival (RFS) when compared to those conditioned with CY-TBI. Status at transplant was also a powerful prognostic indicator. We conclude that preparative regimens consisting of chemotherapy-only seem more efficacious than CY-TBI as conditioning for DLCL, because of faster engraftment and greater anti-lymphoma effect, as indicated by improved OS, DFS and RFS.

Entities:  

Mesh:

Year:  2001        PMID: 11313670     DOI: 10.1038/sj.bmt.1702795

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  17 in total

1.  LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.

Authors:  Navin Khattry; Alok Gupta; Reetu Jain; Adwaita Gore; Ravi Thippeswamy; Nandish Jeevangi; Sadhana Kannan; Reena Nair; Tapan Saikia
Journal:  Int J Hematol       Date:  2016-01-04       Impact factor: 2.490

2.  Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Authors:  Partow Kebriaei; Timothy Madden; Reza Kazerooni; Xuemei Wang; Peter F Thall; Celina Ledesma; Yago Nieto; Elizabeth J Shpall; Chitra Hosing; Muzaffar Qazilbash; Uday Popat; Issa Khouri; Richard E Champlin; Roy B Jones; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-30       Impact factor: 5.742

3.  Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.

Authors:  Yi-Bin Chen; Andrew A Lane; Brent Logan; Xiaochun Zhu; Görgün Akpek; Mahmoud Aljurf; Andrew Artz; Christopher N Bredeson; Kenneth R Cooke; Vincent T Ho; Hillard M Lazarus; Richard Olsson; Wael Saber; Philip McCarthy; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-14       Impact factor: 5.742

4.  Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience.

Authors:  Ilhami Berber; Mehmet Ali Erkurt; Ilknur Nizam; Mustafa Koroglu; Emin Kaya; Irfan Kuku; Harika Gozukara Bag
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.

Authors:  Veronika Bachanova; Ryan Shanley; Farhana Malik; Lata Chauhan; Vishal Lamba; Daniel J Weisdorf; Linda J Burns; Jatinder Kaur Lamba
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-10       Impact factor: 5.742

6.  A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients.

Authors:  Aysun Halacoglu; Songul Serefhanoglu
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-05       Impact factor: 0.900

7.  Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.

Authors:  Philip L McCarthy; Theresa Hahn; Anna Hassebroek; Christopher Bredeson; James Gajewski; Gregory Hale; Luis Isola; Hillard M Lazarus; Stephanie J Lee; Charles F Lemaistre; Fausto Loberiza; Richard T Maziarz; J Douglas Rizzo; Steven Joffe; Susan Parsons; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-06       Impact factor: 5.742

8.  Autologous stem cell transplantation using a modified TAM conditioning regimen for clinically aggressive non-Hodgkin's lymphoma.

Authors:  Sook Hee Hong; Young Seon Hong; In Sook Woo; Yoon Ho Koh; Sang Young Rho; Ji Yean Peak; Myung Ah Lee; Byoung Yong Shim; Jae Ho Byun; Ji Chan Park; Jong Wook Lee; Woo Sung Min; Chun Choo Kim
Journal:  Cancer Res Treat       Date:  2007-06-30       Impact factor: 4.679

9.  Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE.

Authors:  Ahmet Kursad Gunes; Simten Dagdas; Funda Ceran; Mehmet Ali Ucar; Mesude Falay; Cenk Sunu; Meltem Ayli; Nurullah Zengin; Gulsum Ozet
Journal:  Indian J Hematol Blood Transfus       Date:  2020-07-08       Impact factor: 0.900

10.  Autologous stem cell transplantation for aggressive lymphomas.

Authors:  Giuseppe Visani; Paola Picardi; Patrizia Tosi; Roberta Gonella; Federica Loscocco; Teresa Ricciardi; Lara Malerba; Barbara Guiducci; Simona Tomassetti; Sara Barulli; Alessandro Isidori
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-11-07       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.